No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Healthcare Information Services
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
www.alihealth.cnNo one on the platform currently holds 0241.HK.
No tracked institution reports a position in 0241.HK as of their last filing.
No one on the platform has traded 0241.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 12.9% | — | — | — | ||
| Rev. Growth % | 12.0% | 17.2% | ||||
| Profit Margin % | 5.7% | 2.9% | -3.3% | |||
| Free Cash Flow Margin % | 3.6% | 3.0% | -1.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $45.0B | +12.7% | $0.13 | $0.13–$0.15 | — | 8 |
| 2028 | $50.5B | +12.4% | $0.15 | $0.13–$0.17 | — | 9 |
| 2029 | $56.2B | +11.3% | $0.17 | $0.16–$0.18 | — | 3 |
| 2030 | $110.3B | +96.2% | $0.53 | $0.50–$0.55 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | $0.06 | $0.07 | +20.0% |
| 2025-11-26 | $0.09 | $0.09 | +5.2% |
| 2025-05-18 | $0.08 | $0.06 | -14.3% |
| 2024-11-13 | $0.07 | $0.07 | +1.2% |
| 2024-05-27 | $0.05 | $0.06 | +20.0% |
| 2023-11-27 | $0.01 | $0.04 | +228.9% |
| 2023-05-23 | $0.03 | $0.03 | +0.0% |
| $16.22 |
| +5.05% |
| $40.6B |
| — |
| 2196.HKShanghai Fosun Pharmaceutical (Group) Co., Ltd. | $17.12 | +4.84% | $64.1B | — |
| 2268.HKWuXi XDC Cayman Inc | $75.80 | +5.13% | $96.0B | — |
Source: Financial Modeling Prep · peers by sector/industry